

# Craig R Lee

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8902212/craig-r-lee-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100  
papers

4,834  
citations

41  
h-index

68  
g-index

113  
ext. papers

5,548  
ext. citations

4.8  
avg. IF

5.25  
L-index

#	Paper	IF	Citations
100	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.. <i>Clinical Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	14
99	Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e024159	6	1
98	The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 1261-1279	5.5	0
97	Implementation and Initial Evaluation of a Research and Scholarship Training Pathway in a Doctor of Pharmacy Curriculum. <i>American Journal of Pharmaceutical Education</i> , <b>2021</b> , 85, 8079	2.5	3
96	How-To Guide for Overcoming Barriers of Research and Scholarship Training in Pharm.D. and Pharmacy Residency Programs. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2021</b> , 4, 743-753	1.4	3
95	Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 655320	5.6	3
94	Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 110, 412-421	3.9	5
93	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 705-715	6.1	8
92	How-to guide for overcoming barriers of research and scholarship training in Pharm.D. and pharmacy residency programs. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2021</b> , 4, 743-753	1.4	2
91	Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 431-441	2.6	4
90	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 191-200	6.1	89
89	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , <b>2020</b> , 20, 724-735	3.5	11
88	Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2020</b> , 13, 239-252	2.1	6
87	Effect of Gender on Clinical Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , <b>2020</b> , 13, 554-556	5.2	1
86	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>Value in Health</i> , <b>2020</b> , 23, 61-73	3.3	17
85	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 160-169	8.1	28
84	Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2019</b> , 98, 106590	1.7	17

83	Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 647-652	9.4	29
82	A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty. <i>Future Cardiology</i> , <b>2019</b> , 15, 251-254	1.3	4
81	Logistical Challenges Associated With Implementing Precision Medicine. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1300-1306	16.2	1
80	CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , <b>2019</b> , 12, e002441	5.2	9
79	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 664-674	6.1	64
78	Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e002069	5.2	41
77	Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 215-226	3.5	2
76	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 181-191	5	156
75	Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1039-1046	2.6	18
74	Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2018</b> , 138, 15-22	3.7	3
73	Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2018</b> , 134, 24-31	3.7	9
72	Response by Lee and Stouffer to Letter Regarding Article, "Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention". <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e002258	5.2	5
71	Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 771-782	2.6	10
70	Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 517-524	2.4	57
69	The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. <i>Clinical and Translational Science</i> , <b>2017</b> , 10, 143-146	4.9	54
68	CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1155-1166	2.6	24
67	Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 2895-2911	5.8	18
66	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. <i>Clinical and Translational Science</i> , <b>2017</b> , 10, 443-454	4.9	34

65	Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 670-680	15.9	19
64	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1944-1954	2.2	23
63	Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2016</b> , 125, 19-29	3.7	19
62	Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium. <i>Experimental Neurology</i> , <b>2016</b> , 279, 75-85	5.7	10
61	Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 109-19	6.3	41
60	Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2015</b> , 120, 139-47	3.7	16
59	Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2015</b> , 11, 1797-807	6	20
58	Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 303-13	2.6	27
57	Resolvin Infectious Inflammation by Targeting the Host Response. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2183-5	59.2	33
56	Epoxyeicosatrienoic acids and cardioprotection: the road to translation. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 74, 199-208	5.8	51
55	The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e110162	3.7	57
54	A renaissance in pharmacy education at the University of North Carolina at Chapel Hill. <i>North Carolina Medical Journal</i> , <b>2014</b> , 75, 48-52	0.6	41
53	Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity. <i>Journal of Lipid Research</i> , <b>2014</b> , 55, 2124-36	6.3	56
52	CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. <i>Hypertension</i> , <b>2014</b> , 64, 1352-61	8.5	56
51	Highlights from recent advances in antiplatelet pharmacogenomics. <i>Personalized Medicine</i> , <b>2014</b> , 11, 135-138	2.2	
50	Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. <i>FASEB Journal</i> , <b>2014</b> , 28, 2915-31	0.9	27
49	Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2013</b> , 104-105, 67-73	3.7	17
48	Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. <i>Atherosclerosis</i> , <b>2013</b> , 227, 442-8	3.1	54

47	Epoxyeicosanoids promote organ and tissue regeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 13528-33	11.5	102
46	Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. <i>PLoS ONE</i> , <b>2013</b> , 8, e61244	3.7	28
45	Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. <i>Atherosclerosis</i> , <b>2012</b> , 222, 530-6	3.1	77
44	Research Highlights: Highlights from the latest articles in personalized cardiovascular medicine. <i>Personalized Medicine</i> , <b>2012</b> , 9, 363-366	2.2	
43	Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2012</b> , 99, 68-78	3.7	34
42	Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 651-7	3	43
41	Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2012</b> , 302, E500-9	6	36
40	Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 620-8	1.9	36
39	Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 178-91	15.9	208
38	Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 22-9	4	92
37	Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. <i>Hypertension</i> , <b>2011</b> , 57, 116-22	8.5	45
36	Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. <i>FASEB Journal</i> , <b>2011</b> , 25, 703-13	0.9	100
35	Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. <i>FASEB Journal</i> , <b>2011</b> , 25, 3436-47	0.9	90
34	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. <i>FASEB Journal</i> , <b>2010</b> , 24, 3770-81	0.9	116
33	Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2010</b> , 48, 331-41	5.8	137
32	The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 2021-30	2.9	11
31	High-impact articles related to the management of heart failure: 2008 update. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 82-120	5.8	7
30	Key Articles Relative to Cardiovascular Pharmacogenomics. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 1110-1151	5.8	3

29	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 1799-817	2.6	81
28	Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 52-60	6.1	69
27	Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 1369-83	2.6	41
26	Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2007</b> , 293, H142-51	5.2	95
25	Warfarin dosing and the promise of pharmacogenomics. <i>Current Clinical Pharmacology</i> , <b>2007</b> , 2, 11-21	2.5	15
24	CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 349-58	1.9	74
23	Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 145-60	1.9	42
22	Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. <i>American Heart Journal</i> , <b>2007</b> , 153, 1074-80	4.9	29
21	Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. <i>Circulation Research</i> , <b>2006</b> , 99, 442-50	15.7	161
20	Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 1640-9	5.6	152
19	Relationship of Clinical Signs and Chest-X Ray Congestion to the Efficacy of Digoxin in Patients with Chronic Heart Failure: A Retrospective Analysis of the Digoxin Investigation Group Trial. <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, S87-S88	3.3	37
18	NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities study. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 891-9	1.9	22
17	The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. <i>Human Molecular Genetics</i> , <b>2005</b> , 14, 2829-37	5.6	82
16	Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 497-504	15.1	192
15	Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. <i>Pharmacogenetics and Genomics</i> , <b>2005</b> , 15, 227-34	1.9	141
14	beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 127-37	6.1	106
13	Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 315-6	2.8	1
12	Warfarin initiation and the potential role of genomic-guided dosing. <i>Clinical Medicine and Research</i> , <b>2005</b> , 3, 205-6	1.4	5

11	High-impact articles related to the pharmacotherapeutic management of systolic heart failure. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 1594-633	5.8	8
10	Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 84-91	2.9	73
9	Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 58, 791-4	2.8	46
8	Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. <i>Pharmacotherapy</i> , <b>2003</b> , 23, 720-5	5.8	27
7	Vasopressin: a new target for the treatment of heart failure. <i>American Heart Journal</i> , <b>2003</b> , 146, 9-18	4.9	171
6	Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 562-71	6.1	45
5	Surrogate end points in heart failure. <i>Annals of Pharmacotherapy</i> , <b>2002</b> , 36, 479-88	2.9	9
4	Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. <i>Pharmacogenetics and Genomics</i> , <b>2002</b> , 12, 251-63		585
3	Difficulties in anticoagulation management during coadministration of warfarin and rifampin. <i>Pharmacotherapy</i> , <b>2001</b> , 21, 1240-6	5.8	41
2	Low-Molecular-Weight Heparin Therapy in Acute Coronary Syndromes. <i>Hospital Pharmacy</i> , <b>2000</b> , 35, 955-963		
1	The essential research curriculum for doctor of pharmacy degree programs 2021. <i>JACCP Journal of the American College of Clinical Pharmacy</i> ,	1.4	1